PURPOSE: Several sustained-release @entity1286 (SRM) formulations are available internationally. This study compared 2 such products available in the United States, SR1 and SR2. @entity1 AND METHODS: In an open-label study, @entity1 with @entity5 @entity158 were randomized to receive SR1 or SR2 every 12 hours around-the-clock (ATC) for 5 days, with immediate release (IR) liquid @entity1286 for rescue dosing (RD). Efficacy, safety, and @entity1 acceptability were determined. RESULTS: A total of 32 @entity1 were evaluable for efficacy and @entity137 . @entity158 scores, RD dosage, RD frequency over 5 days, RD within 3 hours before and after the scheduled SRM, and 8 of the 11 evaluated side effects were higher in the SR1 group. At presumed @entity1286 steady state (day 3), @entity158 scores (P = .05), RD dosage (P = .07), RD frequency (P = .07), and number of RD +/-3 hours from scheduled SRM dose (P = .05) were consistently greater in the SR1 group (despite a higher median @entity1286 dose in that group). There was a clinically important and directionally consistent trend that favored SR2, although not all were statistically significant. @entity1 preference favored SR2 (P < .05). Neither group had difficulty swallowing SR1 or SR2. CONCLUSIONS: This is the first study that directly compared two 12-hour SRM formulations. The data suggested, by multiple clinically important measures, that SR2 may provide superior analgesic efficacy and less @entity137 compared to SR1. It also supports the concept that it cannot be assumed that different SR formulations of a given opioid are clinically equivalent. A larger study is needed to confirm our findings.

A comparative study of 2 sustained-release @entity1286 preparations for @entity158 in XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS', 'Patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity5 :: ('MESH:D009369', 'Disease') :: ['advanced cancer'] @entity158 :: ('MESH:D010146', 'Disease') :: ['Pain', 'pain'] @entity1286 :: ('MESH:D009020', 'Chemical') :: ['morphine']
@entity5 :: (MESH:D009369,Disease) :: ['advanced cancer']
